299 related articles for article (PubMed ID: 31501268)
21. PTEN hamartoma tumor syndrome: clinical risk assessment and management protocol.
Ngeow J; Eng C
Methods; 2015 May; 77-78():11-9. PubMed ID: 25461771
[TBL] [Abstract][Full Text] [Related]
22. Sirolimus treatment of severe PTEN hamartoma tumor syndrome: case report and in vitro studies.
Schmid GL; Kässner F; Uhlig HH; Körner A; Kratzsch J; Händel N; Zepp FP; Kowalzik F; Laner A; Starke S; Wilhelm FK; Schuster S; Viehweger A; Hirsch W; Kiess W; Garten A
Pediatr Res; 2014 Apr; 75(4):527-34. PubMed ID: 24366516
[TBL] [Abstract][Full Text] [Related]
23. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.
Saintigny P; Mitani Y; Pytynia KB; Ferrarotto R; Roberts DB; Weber RS; Kies MS; Maity SN; Lin SH; El-Naggar AK
Cancer; 2018 Sep; 124(18):3693-3705. PubMed ID: 30289966
[TBL] [Abstract][Full Text] [Related]
24. A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes.
Rodríguez-Escudero I; Oliver MD; Andrés-Pons A; Molina M; Cid VJ; Pulido R
Hum Mol Genet; 2011 Nov; 20(21):4132-42. PubMed ID: 21828076
[TBL] [Abstract][Full Text] [Related]
25. Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase.
Chagpar RB; Links PH; Pastor MC; Furber LA; Hawrysh AD; Chamberlain MD; Anderson DH
Proc Natl Acad Sci U S A; 2010 Mar; 107(12):5471-6. PubMed ID: 20212113
[TBL] [Abstract][Full Text] [Related]
26. PTEN-mediated Akt/β-catenin/Foxo1 signaling regulates innate immune responses in mouse liver ischemia/reperfusion injury.
Kamo N; Ke B; Busuttil RW; Kupiec-Weglinski JW
Hepatology; 2013 Jan; 57(1):289-98. PubMed ID: 22807038
[TBL] [Abstract][Full Text] [Related]
27. Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase.
Luo J; Sobkiw CL; Logsdon NM; Watt JM; Signoretti S; O'Connell F; Shin E; Shim Y; Pao L; Neel BG; Depinho RA; Loda M; Cantley LC
Proc Natl Acad Sci U S A; 2005 Jul; 102(29):10238-43. PubMed ID: 16006513
[TBL] [Abstract][Full Text] [Related]
28. Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome.
Orloff MS; Eng C
Oncogene; 2008 Sep; 27(41):5387-97. PubMed ID: 18794875
[TBL] [Abstract][Full Text] [Related]
29. β-catenin regulates innate and adaptive immunity in mouse liver ischemia-reperfusion injury.
Ke B; Shen XD; Kamo N; Ji H; Yue S; Gao F; Busuttil RW; Kupiec-Weglinski JW
Hepatology; 2013 Mar; 57(3):1203-14. PubMed ID: 23081841
[TBL] [Abstract][Full Text] [Related]
30. The functions of tumor suppressor PTEN in innate and adaptive immunity.
Chen L; Guo D
Cell Mol Immunol; 2017 Jul; 14(7):581-589. PubMed ID: 28603282
[TBL] [Abstract][Full Text] [Related]
31. Hamartoma-like lesions in the mouse retina: an animal model of
Tachibana N; Touahri Y; Dixit R; David LA; Adnani L; Cantrup R; Aavani T; Wong RO; Logan C; Kurek KC; Schuurmans C
Dis Model Mech; 2018 May; 11(5):. PubMed ID: 29716894
[No Abstract] [Full Text] [Related]
32. Cowden's syndrome with immunodeficiency.
Browning MJ; Chandra A; Carbonaro V; Okkenhaug K; Barwell J
J Med Genet; 2015 Dec; 52(12):856-9. PubMed ID: 26246517
[TBL] [Abstract][Full Text] [Related]
33. miRNA92a targets KLF2 and the phosphatase PTEN signaling to promote human T follicular helper precursors in T1D islet autoimmunity.
Serr I; Fürst RW; Ott VB; Scherm MG; Nikolaev A; Gökmen F; Kälin S; Zillmer S; Bunk M; Weigmann B; Kunschke N; Loretz B; Lehr CM; Kirchner B; Haase B; Pfaffl M; Waisman A; Willis RA; Ziegler AG; Daniel C
Proc Natl Acad Sci U S A; 2016 Oct; 113(43):E6659-E6668. PubMed ID: 27791035
[TBL] [Abstract][Full Text] [Related]
34. Pten loss in the mouse thyroid causes goiter and follicular adenomas: insights into thyroid function and Cowden disease pathogenesis.
Yeager N; Klein-Szanto A; Kimura S; Di Cristofano A
Cancer Res; 2007 Feb; 67(3):959-66. PubMed ID: 17283127
[TBL] [Abstract][Full Text] [Related]
35. Inactivation of the tumour suppressor, PTEN, in smooth muscle promotes a pro-inflammatory phenotype and enhances neointima formation.
Furgeson SB; Simpson PA; Park I; Vanputten V; Horita H; Kontos CD; Nemenoff RA; Weiser-Evans MC
Cardiovasc Res; 2010 May; 86(2):274-82. PubMed ID: 20051384
[TBL] [Abstract][Full Text] [Related]
36. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.
Martin AM; Nirschl TR; Nirschl CJ; Francica BJ; Kochel CM; van Bokhoven A; Meeker AK; Lucia MS; Anders RA; DeMarzo AM; Drake CG
Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):325-32. PubMed ID: 26260996
[TBL] [Abstract][Full Text] [Related]
37. Oocyte-specific deletion of Pten in mice reveals a stage-specific function of PTEN/PI3K signaling in oocytes in controlling follicular activation.
Jagarlamudi K; Liu L; Adhikari D; Reddy P; Idahl A; Ottander U; Lundin E; Liu K
PLoS One; 2009 Jul; 4(7):e6186. PubMed ID: 19587782
[TBL] [Abstract][Full Text] [Related]
38. PTEN in liver diseases and cancer.
Peyrou M; Bourgoin L; Foti M
World J Gastroenterol; 2010 Oct; 16(37):4627-33. PubMed ID: 20872961
[TBL] [Abstract][Full Text] [Related]
39. Mutation-positive and mutation-negative patients with Cowden and Bannayan-Riley-Ruvalcaba syndromes associated with distinct 10q haplotypes.
Pezzolesi MG; Li Y; Zhou XP; Pilarski R; Shen L; Eng C
Am J Hum Genet; 2006 Nov; 79(5):923-34. PubMed ID: 17033968
[TBL] [Abstract][Full Text] [Related]
40. PTEN deficiency in mast cells causes a mastocytosis-like proliferative disease that heightens allergic responses and vascular permeability.
Furumoto Y; Charles N; Olivera A; Leung WH; Dillahunt S; Sargent JL; Tinsley K; Odom S; Scott E; Wilson TM; Ghoreschi K; Kneilling M; Chen M; Lee DM; Bolland S; Rivera J
Blood; 2011 Nov; 118(20):5466-75. PubMed ID: 21926349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
